相关实验视频
Updated: Jul 9, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
怀孕期间的抗糖尿病治疗:意大利的处方模式
Anna Locatelli1, Sara Ornaghi1, Alessandra Terzaghi1
1School of Medicine and Surgery, University of Milano-Bicocca, Via Pergolesi 33, 20900 Monza, Italy.
International journal of environmental research and public health
|December 8, 2023
概括
意大利的孕妇糖尿病管理显示一般指南的遵守,但区域差异较大,在多胎和外国妇女中使用抗糖尿病药物的比例较高. 尽管有建议,但实践仍然异质.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 妊娠期和妊娠期糖尿病是一种需要血糖控制的重大妊娠并发症.
- 抗糖尿病药物的使用旨在改善孕产妇和产前期的结果.
- 意大利的指导方针建议在怀孕期间治疗糖尿病的具体方法.
研究的目的:
- 分析意大利怀孕前,怀孕期间和怀孕后的抗糖尿病药物处方模式.
- 评估是否遵守意大利糖尿病治疗指南.
- 识别意大利各地区和人口群体处方实践的差异.
主要方法:
- 一个多数据库,横截面人口研究,利用一个共同的数据模型.
- 分析了大约45万名女性的队列.
- 对抗糖尿病药物的处方数据的检查.
主要成果:
- 处方模式通常与指导方针保持一致,尽管高达3.8%的孕妇在第三季度使用非推的口服抗糖尿病药物.
- 观察到处方模式的区域差异很大,托斯卡纳的增长率最高 (4.2%),伦巴第的增长率最低 (1.5%).
- 与单独分娩和意大利妇女相比,多产妇和外国妇女的抗糖尿病药物消费量分别较高.
结论:
- 虽然意大利实践在很大程度上遵循妊娠糖尿病的指导方针,但存在异质性,特别是在口服抗糖尿病药物方面.
- 区域差异和在特定的人口统计学 (多胎儿,外国妇女) 中使用的增加突出了针对性干预的领域.
- 可能需要进一步的研究来理解和解决怀孕期间抗糖尿病药物处方观察到的变异性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179
Pathophysiology of Diabetes
949
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
949

